Protalix BioTherapeutics (PLX) Revenue (2016 - 2025)
Historic Revenue for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $17.9 million.
- Protalix BioTherapeutics' Revenue fell 60.14% to $17.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.8 million, marking a year-over-year increase of 3541.51%. This contributed to the annual value of $53.4 million for FY2024, which is 1846.73% down from last year.
- Per Protalix BioTherapeutics' latest filing, its Revenue stood at $17.9 million for Q3 2025, which was down 60.14% from $15.7 million recorded in Q2 2025.
- In the past 5 years, Protalix BioTherapeutics' Revenue registered a high of $35.1 million during Q2 2023, and its lowest value of $3.7 million during Q1 2024.
- Its 5-year average for Revenue is $13.1 million, with a median of $11.3 million in 2021.
- Its Revenue has fluctuated over the past 5 years, first soared by 30071.98% in 2023, then plummeted by 6158.52% in 2024.
- Quarter analysis of 5 years shows Protalix BioTherapeutics' Revenue stood at $8.5 million in 2021, then rose by 0.8% to $8.6 million in 2022, then increased by 21.69% to $10.5 million in 2023, then skyrocketed by 73.74% to $18.2 million in 2024, then fell by 2.01% to $17.9 million in 2025.
- Its Revenue was $17.9 million in Q3 2025, compared to $15.7 million in Q2 2025 and $10.1 million in Q1 2025.